Clinical Proof Cellanyx has demonstrated clinical proof of concept for its prostate cancer and Stage 0 breast cancer phenotypic biomarker tests, suggesting strong value in risk stratification and treatment decision support that can appeal to urology and oncology clinics seeking improved pathology augmentation.

Prostate Focus The core product targets enhanced risk stratification at radical prostatectomy for low to intermediate Gleason scores, a high-need segment within community and academic centers, presenting a clear entry path for collaboration with urology and pathology departments.

Tech Advantage Leverage Cellanyx’s combination of rapid primary tumor cell culture, microfluidics, microscopy, and AI-driven phenotypic analysis as a differentiator to position offerings alongside or integrated with existing pathology workflows and imaging platforms.

Low Scale, High Impact With a small team and early-stage revenue, there is a compelling opportunity to target niche institutions and contract research organizations that need novel biomarker-based decision support, enabling scalable pilots before broader commercialization.

Strategic Partnerships Potential sales opportunities exist through collaboration with large oncology laboratories, hospital networks, and cancer centers looking to augment their biomarker portfolio, as well as leveraging advisory board connections (e.g., board member appointments) to accelerate clinical adoption.